Cara Care App Review: Two Apps, One Name

Before you can review Cara Care, you have to work out which Cara Care you mean. There are two, they do completely different things, and only one of them has a clinical trial behind it.

One is a free food and symptom tracker in English, the app that most blog reviews and most Reddit threads are actually talking about. The other is Cara Care fuer Reizdarm, a prescription-only digital therapy listed in Germany's official register of digital health applications, paid for by German statutory health insurance, and built around a 12-week programme of dietary content, cognitive behavioural therapy material and gut-directed hypnotherapy.

The gap between the two is large. The German version has a 378-person randomised controlled trial and was permanently listed by the German regulator in November 2023. The English tracker's most recent update on both major app stores was in October 2020. In between those two facts sits a company that changed owners twice and passed through insolvency proceedings.

This review works through all of that using primary sources: the regulator's own entry, the clinical trial registration, the company's own press release, and the app store listings themselves. Where a number could not be verified, it says so.

The short answer: which Cara Care are you asking about?

If you are in Germany, have an IBS diagnosis and can get a prescription, Cara Care is a 12-week structured therapy programme with a randomised trial behind it, and it costs you nothing at the point of use. On that basis it is one of the better evidenced gut apps available anywhere, with caveats that this article spends most of its length on.

If you are anywhere else, Cara Care is a food and symptom tracker whose last release was in October 2020. Judged as a tracker in 2026 it is dated, and the specific complaints people raise about it in r/ibs are the predictable consequences of a tracker that stopped being developed.

Almost every English-language "Cara Care app review" you will find merges these two into a single verdict. That is the main reason the reviews are confusing.

Two apps, one name: how to tell which one you have

The quickest way to tell them apart is the store listing and the way you get in.

Those update dates are not opinion. They are the dates the stores themselves show against each listing, and I checked them directly rather than taking them from a review. The English iOS tracker sits on version 5.4.5 with a release date of 27 October 2020 and a minimum requirement of iOS 10. The German listing was on version 2.1.28 at the start of September 2026.

A minimum requirement of iOS 10 in 2026 tells you something on its own. Nobody has recompiled that app against a modern SDK in almost six years.

What the German prescription version actually does

The regulator's own description is unusually detailed, which is one of the underrated benefits of a product having to be registered at all.

Cara Care fuer Reizdarm is described as an interactive, software-based medical application for self-use in the treatment of irritable bowel syndrome, coded to ICD-10-GM K58 and its subtypes. The stated effects are achieved through what the entry calls a multimodal self-help concept: personalised content drawn from guideline-concordant approaches in nutrition, specifically the low FODMAP diet, and psychotherapy, specifically cognitive behavioural therapy and gut-directed hypnotherapy.

That combination is not arbitrary. All three are in the current German S3 guideline for irritable bowel syndrome (Layer 2021), and all three appear in the British Society of Gastroenterology guidelines (Vasant 2021) and the American College of Gastroenterology guideline (Lacy 2021). Packaging three separately evidenced approaches into one 12-week app is a reasonable idea, and it is the most genuinely interesting thing about the product.

Mechanically, the programme runs like this. An intake questionnaire feeds an algorithm that determines which content you see. Over a minimum use period of 12 weeks you work through text and audio modules on your own. Personalised food lists and recipes support the dietary part, a goal-setting function supports the behavioural part, a quiz function reinforces the educational content, and a diary tracks food, lifestyle factors and symptoms. Symptom and quality-of-life scores are re-asked at intervals and fed back to you as a progress report. A built-in symptom check flags red-flag symptoms that need medical assessment.

The regulator also records the limits plainly. It must not be used in pregnancy, it is intended for ages 18 to 70, a medical diagnosis and indication are mandatory, and it explicitly does not replace medical treatment. Modules are not unlocked, or are stopped part-way, if you report a contraindication.

The trial behind it, read properly

This is the part no English-language review covers, so it is worth going through carefully.

The study is registered as DRKS00026631 in the German Clinical Trials Register. It was registered prospectively on 6 October 2021, started recruiting on 15 December 2021 and completed on 27 February 2024. The sponsor and funder was HiDoc Technologies GmbH, the company that made the app. The principal investigator was based at the university medical centre in Brandenburg an der Havel, with recruitment also through the Charite in Berlin and two other Berlin sites. Ethics approval came from the Medical School Brandenburg ethics committee.

Target sample size was 374 and the final sample was 378, randomised 188 to the intervention group and 190 to control. Outcomes were collected at four weeks, six weeks and twelve weeks, with twelve weeks as the primary endpoint.

Here are the results as the regulator records them, comparing change from baseline to 12 weeks between groups:

All five endpoints were tested in a pre-specified hierarchical strategy, all reached p below 0.0001, and the regulator judged the requirements for permanent listing met on four claimed care effects: improvement in health status, improvement in quality of life, coping with disease-related difficulties in everyday life, and health literacy.

For scale, the best-known trial of web-delivered CBT for IBS, the ACTIB trial, found web CBT produced an IBS-SSS score 35.2 points lower than treatment as usual at 12 months, and telephone CBT 61.6 points lower (Everitt 2019). ACTIB recruited people with refractory IBS and measured at a year rather than 12 weeks, so this is not a like-for-like comparison. But it is the reference point a gastroenterologist would reach for, and Cara Care's reported difference is larger than either ACTIB arm.

The two numbers on the website do not match each other

The current English Cara Care homepage carries a headline claim: "70,2% of participants in the study showed clinically relevant symptom improvement." The figure is followed by an asterisk and linked directly to the company's own press release about the study results.

That press release, dated 17 October 2023 and issued from Hamburg, gives a different number. It states that 66.5 percent of the intervention group, 125 of 188, recorded a clinically relevant improvement in symptoms, against 33.2 percent in the control group.

I am not going to guess at which is right or why they differ. Both are plausible readings of the same dataset: 70.2 percent could be a per-protocol figure against 66.5 percent intention-to-treat, or a figure from a different responder definition. The honest position is that there is no way to reconcile them from the public record, because the trial has never been published. The regulator's entry confirms that responder analyses were done but does not give the numbers.

That is a small thing on its own. It matters because it is the one number a prospective user is most likely to remember, and it is the number a reviewer would repeat without checking the source it links to.

Why an unblinded app trial in IBS needs a bigger discount than most

Two facts about the study design deserve more attention than the effect sizes.

First, the trial was not blinded. The registry records blinding as "no". The control group received an app containing only the assessment questionnaires, and after 12 weeks they were given the real programme too. So participants knew perfectly well whether they had been given a therapy or a set of forms. Second, every single outcome was a self-reported questionnaire: symptom severity, quality of life, work and activity impairment, health literacy, anxiety and low mood.

In most conditions that combination is a moderate concern. In IBS it is a large one, because IBS has one of the biggest placebo responses in medicine. A meta-analysis of 73 randomised trials covering 8,364 patients allocated to placebo found a pooled placebo response rate of 37.5 percent, with a confidence interval of 34.4 to 40.6 percent (Ford 2010). Cara Care's control group response rate of 33.2 percent sits comfortably inside that range, which is a good sign that the control arm behaved normally.

The intervention arm is the question. And IBS is the condition where researchers demonstrated that you do not even need to conceal a placebo for it to work. In a randomised trial, patients openly told they were receiving inert placebo pills still improved significantly more than a no-treatment control with matched practitioner contact (Kaptchuk 2010). A later three-arm trial found open-label placebo produced a mean IBS-SSS improvement of 90.6 points against 52.3 for no pill, and was not significantly different from double-blind placebo (Lembo 2021).

Read those two trials next to the Cara Care numbers and the point becomes uncomfortable. Openly labelled sugar pills moved the same scale by roughly 90 points in six weeks. A twelve-week programme of daily engagement, personalised content and progress feedback, given to people who know they have been allocated the real thing, has every ingredient needed to generate a large expectation effect on a self-reported scale.

This is not a Cara Care problem specifically. It is the structural weakness of the whole German digital health application evidence pathway. An independent assessment of the permanently listed applications in the nervous system and mental health categories, using the Cochrane risk-of-bias tool, found that every one of the six randomised trials assessed showed a high risk of bias, primarily because of lack of blinding. The same review noted that dropouts were substantially higher in the intervention group than the control group in most of those studies, and recommended that future trials compare the application against a sham application to reduce bias (Kolominsky-Rabas 2022).

The dropout pattern nobody mentions

Cara Care's trial reproduces the second half of that criticism almost exactly.

Of 378 participants, 10 were recorded as dropouts at the 12-week point. All ten were in the intervention group: 5.32 percent of the intervention arm and 0.0 percent of the control arm.

Ten out of 378 is a low overall dropout rate, and by the standards of digital health trials it is genuinely good. But the asymmetry is total. Nobody who was given the questionnaire-only app left the study. Everybody who left had been given the real programme.

The German review flagged exactly this pattern, and listed the three explanations worth considering: lack of efficacy in the intervention group, technical problems with the application, or lack of motivation among participants (Kolominsky-Rabas 2022). There is a fourth, more mundane one: answering four rounds of questionnaires is less work than a twelve-week daily programme, so the intervention arm simply had more to drop out of. A published paper would let you look at when and why those ten left. There is no published paper.

That is the single biggest limitation on any honest review of this app. The trial looks well designed on the points a registry can capture: prospectively registered, adequately powered, multicentre, hierarchical testing strategy, intention-to-treat primary analysis, consistent subgroup results by age, sex, subtype and time since diagnosis. But nobody outside the company and the regulator has been able to interrogate it.

It is also worth naming who is connected to what. The trial was sponsored and funded by the manufacturer. The evaluation was carried out by a commissioned research institute. The gastroenterologist credited in the regulator's entry with supporting the design of the hypnotherapy module is also a co-author of the German S3 IBS guideline that the app cites as its evidence base. None of that is improper, and it is all disclosed in the registry and the press release rather than hidden. It does mean that the guideline concordance and the product design were not arrived at independently of one another.

What happened to the company

This matters more than it sounds, because a symptom diary is a multi-year asset and you are trusting somebody to keep it.

The app was built by HiDoc Technologies GmbH, a German digital health startup. The trail after that is documented by the M&A advisor that worked on both transactions:

• February 2024. Mahana Therapeutics Inc., a US digital therapeutics company, finalised the acquisition of Cara Care (HiDoc Technologies GmbH), described at the time as creating a global leader in digital treatment of chronic conditions.
• June 2024. Mahana announced it had secured permanent reimbursement in Germany for the Cara Care IBS digital therapeutic. The regulator's own change history dates the permanent listing to 24 November 2023.
• October 2024. Cara Care entered debtor-in-possession insolvency proceedings in Germany.
• December 2024. Bayer AG entered a takeover agreement, with the transaction expected to close in spring 2025. The advisor's record states that its team advised the insolvency administrator and Cara Care.

Eight months separated the "global leader" acquisition and the insolvency filing. Mahana's own domain now redirects to a different brand entirely. The Cara Care website imprint still names HiDoc Technologies GmbH in Hamburg as the operating entity, represented by a Bayer Consumer Health marketing manager.

The practical reading is straightforward. The prescription product survived, is being actively updated and is backed by one of the largest pharmaceutical companies in the world, which on balance makes it more likely to still exist in three years than most gut apps. The English consumer tracker did not survive in any meaningful sense, and the corporate turbulence of 2024 is the most plausible explanation for why.

What people in r/ibs actually report about the tracker

Reddit is not evidence about whether an app works, but it is the most reliable record of what using one is like. The recurring complaints about the English tracker are consistent and specific.

The best-versus-worst-day analysis returns the same foods on both sides. The thread that prompted this review is a post asking whether the app is useful at all, from someone who had logged food, symptoms, bowel movements and exercise for weeks and found the dashboard listing nearly identical foods as their best-day and worst-day foods (r/ibs thread). A reply described the same experience and deleted the app. Another commenter offered the correct diagnosis: if you eat broadly the same things most days, a comparison of good days against bad days has nothing to separate.

That is not a bug, and no amount of extra logging fixes it. It is the arithmetic of the method. The same limitation applies to every tracker that offers correlation dashboards, and it is why a planned challenge beats a chart. Our guide on finding out what actually triggers your IBS covers how a challenge and rechallenge is structured.

You cannot log at ingredient level, and the database misses things. One poster described downloading Cara Care and finding that everything had to be manually entered and most ingredients were not in the database (r/ibs thread). Another, in the original thread, noted the app would not let you enter ingredients, only foods, and could not separate meals. A diary built around ingredient-level logging works differently, as our mySymptoms food diary app review sets out.

It does not scan. A post comparing options states plainly that Cara Care tracks manual input but does not scan barcodes (r/ibs thread). That was a normal limitation for a 2020 app and is a conspicuous one now, though scanning brings its own problems that we cover in the low FODMAP barcode scanner guide.

It will not connect this morning's symptoms to last night's dinner. Someone asked exactly that before committing to logging everything, describing morning symptoms with nothing eaten yet and wondering whether the app would make the link back to the previous evening (r/ibs thread). Delayed reactions are ordinary in IBS, and a same-day correlation will miss them.

Availability is patchy outside Germany. A newly diagnosed UK user on Android posted that every tracker they had seen recommended was unavailable to them, naming Cara Care specifically (r/ibs thread).

People have been told the service is ending. A 2026 post asking for food tracker recommendations opens with the line that they had been using Cara Care but the service was going to end (r/ibs thread). That is one person's report, not a confirmed company announcement, and I could not find a public notice to corroborate it. It sits alongside a store listing that has not been updated in almost six years, which makes it credible without making it verified. Note also that two of the replies in that thread are from people promoting their own apps, one of whom discloses it and one of whom does not.

Nobody answered the hypnotherapy question. A post asking whether Cara Care's hypnotherapy component was worth it, or whether Nerva was the better option, received zero replies (r/ibs thread). That is a small data point but a telling one: the therapy component is the part with the evidence behind it, and the English-speaking community has almost no experience of it.

Can you get it outside Germany? The honest answer

No, not the version with the trial behind it.

Cara Care fuer Reizdarm is distributed through the German App Store and the German Google Play store, and registration requires an access code issued after a doctor establishes the diagnosis and indication, or issued by a statutory health insurer once you provide proof of diagnosis. There is no consumer purchase path. The regulator's entry lists the reimbursement figure as 248 euros for 90 days, paid by statutory health insurance, with no additional cost to the patient.

The English tracker is still listed in some storefronts, is free to download, and has not been maintained since 2020. It is not available in the German storefront at all.

If you are outside Germany and specifically want the therapy components, the realistic route is to reach them separately rather than through this app:

A meta-analysis of antidepressants and psychological therapies in IBS found psychological therapies as a class effective, with the usual caveats about trial quality and the impossibility of blinding (Ford 2019). The point of the table is that none of these three things is locked inside one app. If it is the food lookup part you were after rather than the therapy, what to use instead of the Monash FODMAP app compares the options for that job.

If you are in Germany and have a diagnosis

A few things worth knowing before you start, all taken from the regulator's entry rather than the marketing.

The minimum use period is 12 weeks, and the programme is built around completing it. That is a real commitment, and partial use is the most common way digital interventions fail. The general pattern of people quietly stopping is well enough established in digital health to have its own name (Eysenbach 2005), and our sibling guide on choosing an IBS tracking app covers why tracking habits die in the first month.

You must not use it in pregnancy, and it is intended for ages 18 to 70. A medical diagnosis and indication are mandatory, and the app will not unlock or will stop modules if you report a contraindication as you go.

Your data stays in the EU. The manufacturer states that no personal data flows to a country outside the EU or without an adequacy decision, and the regulator assessed that as compliant. Data portability is provided through an export of therapy and health data in CSV, printable as a PDF.

That export is not a footnote. It is also the mechanism for the thing an app can genuinely add to an appointment: a summary of how symptom severity and quality-of-life scores moved, which your doctor can use to decide whether to adjust treatment outside the app or issue a follow-up prescription. The regulator notes that clinicians have no role inside the app itself.

Finally, there is a caveat that applies to any app teaching the elimination phase of a restrictive diet to someone alone on their phone. Restriction started during a bad patch has a habit of outlasting it, and the reintroduction phase is the part people skip. If your food list is getting shorter rather than longer, that is worth raising with a dietitian.

What the app quality research says about gut apps generally

Two studies are worth knowing, because they set expectations for the whole category.

A systematic search of the German app stores identified 1,764 apps, narrowed to 14 IBD apps meeting the inclusion criteria, and had six physicians rate them with the Mobile Application Rating Scale. Median scores ranged from 2.38 to 4.11 out of 5, and the authors noted a discrepancy between app store ratings and the structured quality ratings, concluding that there is little evidence for the clinical benefit of German IBD apps (Gerner 2022). That is a useful corrective to the instinct to pick by star rating.

A separate evaluation of free commercially available IBD management apps against a taxonomy of 26 behaviour change techniques found that the techniques with the best evidence for changing behaviour are frequently absent from the apps that claim to support self-management (Noser 2023). Tracking is the easy part to build, and the part that actually changes anything is usually the part that is missing.

The one published randomised trial of a consumer low FODMAP app that I could find is instructive about how small this literature is. A pilot trial of the Heali app randomised 58 people, only 25 completed, and the reduction in total IBS symptom severity did not reach significance (Rafferty 2021). That is the state of the field the Cara Care trial sits in: by comparison, 378 participants with 10 dropouts is a serious piece of work, which is precisely why the absence of a publication is frustrating.

There is also research on how differently people rate regulated versus unregulated health apps in Germany, which found systematic differences in how consumer and prescription apps are reviewed (Uncovska 2023). Taken with the wider analyses of the German fast-track pathway (Lantzsch 2022; Gensorowsky 2022) and a recent taxonomy of the market (Cenko 2026), the picture is of a genuinely novel reimbursement system still working out how much evidence it should demand.

Myths about Cara Care

"Cara Care is clinically proven." It has one company-sponsored randomised trial, unblinded, with self-reported outcomes, never published in a peer-reviewed journal. That is meaningfully more than almost any other gut app has, and it is not the same as proven. The regulator judged it sufficient for permanent listing, which is a regulatory decision about a reimbursement category, not a scientific consensus.

"The app is free." The German version costs you nothing because statutory health insurance pays, and you cannot get it without a diagnosis and a code. The English tracker is a free download with paid extras. Neither of those is "free" in the sense people usually mean.

"Cara Care beats medication for IBS." The company press release makes a number-needed-to-treat comparison against antispasmodics, citing a 2005 Cochrane review (Quartero 2005). That review has since been superseded by a 2011 update (Ruepert 2011), and comparing a number needed to treat from an unblinded app trial against one from blinded drug trials is not a fair comparison in either direction. It is a marketing statement, not a finding.

"Cara Care has been shut down." The prescription product is being actively updated. What has stopped is the English tracker, and one r/ibs poster reports being told their service was ending. Do not conflate the two.

"It will find my trigger foods." No tracker does that on its own, and the specific complaint people raise about Cara Care's dashboard is a good illustration of why. A diary makes suspects. A challenge makes triggers. Our guide on keeping a food diary for IBS covers what a diary can and cannot resolve.

"If it has hypnotherapy it must be a gimmick." Gut-directed hypnotherapy has a stronger evidence base than most people assume, including a multicentre trial where individual and group hypnotherapy both beat educational supportive therapy at three and twelve months (Flik 2019). It is in the British and German guidelines. The question is not whether hypnotherapy works but whether an app delivers it as well as a therapist does, and that comparison has not been made.

What to do if an app you rely on shuts down

The most useful thing in the r/ibs thread about Cara Care ending was not the app recommendations. It was a reply pointing out that the part that stings is losing years of logs, and that the first question about any replacement should be where your data actually lives.

That is the right instinct, and it generalises. Before you commit a year of logging to anything:

1. Find the export before you need it. Check you can get a file out, and check what format. CSV you can open in a spreadsheet is worth more than a PDF report you can only read.
2. Export on a schedule, not on a deadline. A copy every few months, stored somewhere that is not the phone, costs nothing and survives a company you had not thought about.
3. Check whether the history stays on the device or on a server. Both are legitimate designs with different failure modes: a server can be switched off, a phone can be lost.
4. Do not switch apps mid-experiment. If you are in the middle of a structured challenge, finish it, then move.

Clairop keeps voice logging and barcode scanning on the same timeline and produces a summary you can take to an appointment, and you can read exactly how that works on the how it works page. Whatever you use, the export question is the one to settle first.

When to talk to a doctor rather than an app

No app, prescription or otherwise, should be the thing standing between you and an assessment. The German version builds in a red-flag check precisely because its makers knew that.

See a doctor promptly if you have any of the following:

• Blood in your stool, or black tarry stools
• Unexplained weight loss
• Fever alongside gut symptoms
• Symptoms that wake you from sleep
• Symptoms of anaemia, such as new breathlessness or unusual fatigue
• New bowel symptoms starting after the age of 50
• A family history of bowel cancer, coeliac disease or inflammatory bowel disease

Also worth a conversation rather than more logging: symptoms that have clearly changed in character, a food list that keeps shrinking, or a level of anxiety about eating that is starting to organise your day. IBS is common, affecting a meaningful share of adults worldwide (Sperber 2021), and the fact that it is common does not make a change in your pattern unimportant.

If stress is the thread running through your symptoms, the gut-brain side has its own evidence base, which we cover in can stress cause an IBS flare up.

The short version

Cara Care is two products. The German prescription therapy is, on the public record, one of the better evidenced gut apps in existence: 378 participants, a prospectively registered randomised trial, a between-group IBS-SSS difference of about twice the threshold for meaningful improvement, and permanent listing by a national regulator. It is also unblinded, entirely self-reported, sponsored by its maker, unpublished, and unavailable to you unless you have a German diagnosis. The intervention-only dropout pattern is worth noticing.

The English tracker is a 2020 app that people still find in search results, with the specific weaknesses you would expect from a tracker that has not been developed since: no ingredient-level logging, no scanning, a best-versus-worst-day comparison that returns the same foods on both sides, and patchy availability outside Germany.

The company that made both went through insolvency in October 2024 and now sits inside Bayer. That is not a reason to avoid the prescription version, which has probably never been more securely funded. It is a reason to treat the export function as the first feature you test, not the last.

If you came here asking whether to download Cara Care: check which country's store you are in. That answers most of it.